Fig. 5From: The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsPFS of patients evaluated as carriers vs not carriers of one or more TP53 mutation (A). PFS of patients stratified as carriers or not of TP53 mutations and their cfDNA amount (B)Back to article page